BBA
EIKN

Baker Bros. Advisors’s Eikon Therapeutics EIKN Stock Holding History

Baker Bros. Advisors’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.25M Hold
555,555
– – 0.04% 73
2026
Q1 		$5.88M Buy
+555,555
New +$7.43M 0.03% 74

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Baker Bros. Advisors's EIKN Position: Q2 2026 in Review

Baker Bros. Advisors held its Eikon Therapeutics (EIKN) position steady in Q2 2026 at 555,555 shares worth $7.25M. The position accounts for 0.04% of the portfolio, ranked #73.

Baker Bros. Advisors first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Baker Bros. Advisors held 555,555 shares of Eikon Therapeutics worth $7.25M as of Q2 2026.
  • Baker Bros. Advisors left its Eikon Therapeutics share count unchanged in Q2 2026.
  • Eikon Therapeutics made up 0.04% of Baker Bros. Advisors's portfolio in Q2 2026, its #73 holding.
  • Baker Bros. Advisors first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.